Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11198767 | 0.86 | — | — | |
| SCHEMBL3841746 | 0.82 | CES1 (0.38) | CES2CES1FAAH | |
| SCHEMBL7263038 | 0.79 | CES2 (0.39) | CES2TSHRCES1ALDH1A1ATM | |
| SCHEMBL2813689 | 0.77 | ADRB2 (0.38) | CES2TSHRCES1ALDH1A1ADRB2 | |
| SCHEMBL7261876 | 0.76 | CES2 (0.37) | CES2TSHRCES1ALDH1A1ATM | |
| SCHEMBL8642592 | 0.75 | ADRB2 (0.36) | CES2TSHRCES1ALDH1A1ADRB2 | |
| SCHEMBL7565286 | 0.74 | CES1 (0.37) | CES2TSHRCES1ALDH1A1ADRB2 | |
| SCHEMBL3838507 | 0.74 | CES1 (0.42) | CES2CES1FAAH | |
| SCHEMBL31425757 | 0.73 | CES1 (0.35) | CES2TSHRCES1ALDH1A1ADRB2 | |
| SCHEMBL9345099 | 0.73 | CES1 (0.35) | CES2TSHRCES1ALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550664-B1 | SILICON COMPOUND | JNC CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1650214-B1 | Silicon compound | CHISSO CORP (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-1686133-B1 | Organosilicon compound | CHISSO CORP (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-7399819-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7375170-B2 | Organosilicon compound | CHISSO CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1849787-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849788-A1 | Organosilicon compound | Chisso Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-7256243-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7235619-B2 | Silsesquioxane derivative | CHISSO CORPORATION (JP) | 2007-06-26 | — | — | US | disclosed |
| US-20060175684-A1 | Organosilicon compound | JNC PETROCHEMICAL CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1686133-A2 | Organosilicon compound | CHISSO CORPORATION (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-7053167-B2 | Silsesquioxane derivative having functional group | CHISSO CORPORATION (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20060094849-A1 | Silicon compound | JNC CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | ITO KENYA | 2006-04-27 | — | — | US | disclosed |
| EP-1650214-A2 | Silicon compound | CHISSO CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | CES2 462/4885TSHR 4284/4885CES1 1338/4885 |
| US-20060089504-A1 | Silsesquioxane derivative having functional group | SFXN1, STS, SRM | CES2 1360/4885TSHR 3118/4885CES1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.